Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (49)

2024

  1. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

    Nature Communications, Vol. 15, Núm. 1

  2. T-Cell Immune Responses in Newborns and Long-Term Sequelae in Congenital Cytomegalovirus Infection (CYTRIC Study)

    Journal of Pediatrics, Vol. 272

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  3. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  4. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

2022

  1. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 11, pp. 2128-2137

  2. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

    European Journal of Health Economics, Vol. 23, Núm. 3, pp. 551-558

  3. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  4. Human genetic and immunological determinants of critical COVID-19 pneumonia

    Nature, Vol. 603, Núm. 7902, pp. 587-598

  5. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

  6. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  7. The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients

    Transplant Immunology, Vol. 75

2021

  1. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

  2. Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study

    Transplant Infectious Disease, Vol. 23, Núm. 2

  3. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515

  2. Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy

    EBioMedicine, Vol. 58

  3. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, Núm. 10, pp. 3342-3347

  4. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 438-443